Orchid Pharma Limited announced the approval of its Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, 2025. The Board of Directors met on February 11, 2026, to ratify these figures, which included auditors’ limited review reports. Key highlights show a significant Exceptional Item charge of ₹711.27 lakhs related to reassessed employee benefits obligations under new labor codes, impacting the reported profit/loss figures for the period.
Board Meeting Outcome and Financial Period
The Board of Directors of Orchid Pharma Limited convened on February 11, 2026, from 01:30 P.M. to 05:15 P.M. (IST). During this meeting, the Board approved the Unaudited limited reviewed Standalone & Consolidated Financial Results for the quarter and nine months ended December 31, 2025. The results were accompanied by the auditors’ limited review reports issued by M/s. Singhi & Co.
Key Financial Performance Snapshot (Standalone – Q3 FY2025 vs. Q2 FY2025)
Total Income for the quarter ending December 31, 2025, stood at ₹21,785.70 lakhs, compared to ₹20,894.94 lakhs in the preceding quarter (Sept 30, 2025). Total Expenses for the period were ₹21,656.86 lakhs. Following the inclusion of an exceptional item, the Profit/(Loss) before tax for the quarter was a loss of ₹(582.43) lakhs.
For the nine months ended December 31, 2025, Total Income reached ₹61,566.56 lakhs, while Total Expenses were ₹59,394.87 lakhs. The resulting Profit/(Loss) before tax for the nine months was ₹1,460.42 lakhs.
Impact of Exceptional Items
A significant note in the results pertains to an exceptional item charge of ₹711.27 lakhs, recorded both in the quarterly and nine-month periods. This charge arises from the reassessment of employee benefits obligations following the consolidation of existing labor legislations into the New ‘Labour Codes,’ leading to an incremental liability for past service costs as per IND AS19 ‘Employee Benefits’.
Consolidated Financial Performance Summary
On a consolidated basis, Total Income for the Q3 FY2025 quarter was ₹21,287.64 lakhs. The consolidated Profit/(Loss) before tax for the quarter showed a loss of ₹(1,214.64) lakhs, which includes the impact of the exceptional item. For the nine months ended December 31, 2025, the consolidated Total Income was ₹60,155.14 lakhs, resulting in a consolidated Profit/(Loss) before tax of ₹(323.32) lakhs.
QIP Fund Utilization Update
The company provided an update on the utilization of proceeds raised via Qualified Institutional Placement (QIP). As of December 31, 2025, ₹33,256 lakhs of the ₹39,454 lakhs total funds received (after adjustment for surplus allocation) had been utilized. The balance unutilized amount remaining in fixed deposits was ₹6,198 lakhs, excluding interest earned.
Auditor’s Review Qualification
The Statutory Auditors, Singhi & Co., issued a modified conclusion on the Limited Review report. Specifically, for the consolidated results, the auditors noted that they did not review the interim financial results of several subsidiaries (Orchid Pharmaceuticals Inc., Bexel Pharmaceuticals Inc., and Diakron Pharmaceuticals Inc.), whose financial information, reflecting Nil revenue and profit/loss, formed part of the consolidated figures. Furthermore, they noted they did not review the financial information of one other subsidiary and had basis for qualification regarding the share of results from an associate.
Earnings Per Share (EPS)
Basic Earnings Per Share (EPS) for the quarter ended December 31, 2025, was a loss of ₹(1.15) per share (Standalone) and ₹(2.49) per share (Consolidated).
Source: BSE
